# Effects of Curcumin/Turmeric Supplementation on Kidney Function in Individuals With Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

**Authors:** Hossein Bahari, Zahra Asadi

PMC · DOI: 10.1002/edm2.70189 · Endocrinology, Diabetes & Metabolism · 2026-02-28

## TL;DR

A review of 12 studies found that curcumin/turmeric supplements may lower urea levels in people with diabetes, but not other kidney markers like creatinine or BUN.

## Contribution

This study is the first to systematically evaluate and meta-analyze the effects of curcumin/turmeric on multiple kidney function parameters in diabetic individuals.

## Key findings

- Curcumin/turmeric significantly reduced urea levels in diabetic individuals.
- No significant effects were observed on creatinine, BUN, uric acid, or albumin levels.
- Publication bias was detected for creatinine, and evidence certainty was moderate to low for most markers.

## Abstract

Curcumin and turmeric are widely studied for their potential renoprotective effects, but evidence regarding their impact on kidney function in individuals with diabetes remains inconsistent.

To systematically evaluate the effects of curcumin/turmeric supplementation on kidney function parameters in subjects with diabetes.

PubMed, Web of Science and Scopus were searched from inception until August 2025. Randomised controlled trials (RCTs) assessing the effects of curcumin/turmeric on serum creatinine, blood urea nitrogen (BUN), uric acid, urea and albumin in diabetic populations were included. Data were pooled using random‐effects models and reported as weighted mean differences (WMDs) with 95% confidence intervals (CIs). Subgroup, sensitivity, and meta‐regression analyses were conducted. Risk of bias was assessed using the Cochrane RoB 2 tool, and evidence certainty was evaluated via GRADE.

Twelve RCTs (n = 1303 participants) were included. Curcumin/turmeric supplementation did not significantly affect creatinine (WMD: −0.01 mg/dL, 95% CI: −0.03 to 0.01, p = 0.519) or BUN (WMD: −0.41 mg/dL, 95% CI: −3.15 to 2.33, p = 0.769). A trend toward reduction in uric acid was observed (WMD: −1.46 mg/dL, 95% CI: −2.93 to 0.02, p = 0.053). However, urea levels were significantly reduced (WMD: −2.53 mg/dL, 95% CI: −4.09 to −0.96, p = 0.002). No significant change was found in albumin (WMD: 0.07 g/dL, 95% CI: −0.02 to 0.17, p = 0.133). Subgroup analyses showed no significant moderating effects. Publication bias was detected for creatinine (Egger's p = 0.028). The certainty of evidence was moderate for creatinine, urea, and albumin, and low for BUN and uric acid.

Curcumin/turmeric supplementation significantly reduces urea levels but does not significantly affect creatinine, BUN, uric acid or albumin in individuals with diabetes. Further high‐quality, long‐term RCTs are needed to clarify its renoprotective potential and optimal dosing.

This meta‐analysis of 12 randomised controlled trials (n = 1303) found that curcumin/turmeric supplementation significantly reduces serum urea levels in individuals with diabetes, but does not significantly affect creatinine, BUN, uric acid or albumin. The findings suggest a potential tubular benefit, though glomerular markers remain unchanged. Further long‐term trials are needed to clarify its renoprotective role.

## Linked entities

- **Chemicals:** curcumin (PubChem CID 969516)
- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}
- **Diseases:** nitrogen (MESH:D007222), inflammation (MESH:D007249), metabolic dysfunction-associated steatotic liver disease (MESH:D008107), CKD (MESH:D051436), Diabetes (MESH:D003920), tubular injury (MESH:D000230), kidney function decline (MESH:D007680), diabetic complications (MESH:D048909), glomerular and tubular injury (MESH:D015499), end-stage renal disease (MESH:D007676), NIDDM (MESH:D003924), kidney damage (MESH:D007674), chronic (MESH:D002908), DKD (MESH:D003928), impaired glucose tolerance (MESH:D018149)
- **Chemicals:** aldosterone (MESH:D000450), CO (MESH:D002248), Uric Acid (MESH:D014527), nitrogen (MESH:D009584), curcuminoid (MESH:D036381), advanced glycation end-product (MESH:D017127), Curcumin (MESH:D003474), piperine (MESH:C008922), Urea (MESH:D014508), Cr (MESH:D002857), lipids (MESH:D008055), urea nitrogen (MESH:C530477), polyphenol (MESH:D059808), Creatinine (MESH:D003404)
- **Species:** Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606], Curcuma longa (turmeric, species) [taxon 136217]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949467/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12949467/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949467/full.md

---
Source: https://tomesphere.com/paper/PMC12949467